Stock CTX CRESCITA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Crescita Therapeutics Inc.

Equities

CTX

CA2258471028

Delayed Toronto S.E.
Other stock markets
 12:32:13 11/05/2024 am IST 		5-day change 1st Jan Change
0.435 CAD 0.00% Intraday chart for Crescita Therapeutics Inc. +1.16% -11.22%
08/05 Crescita Therapeutics Q1 Loss Widens, Revenue Rises MT
08/05 Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Crescita Therapeutics Q1 Loss Widens, Revenue Rises
MT
Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million
MT
Crescita Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Crescita Reports First Quarter 2024 Results
BU
Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share
MT
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.
CI
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Crescita Therapeutics Brief: Q4 EPS Basic and Diluted Loss $0.01
MT
Crescita Reports Q4 and Fiscal 2023 Results
BU
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.
CI
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Crescita Reports Third Quarter 2023 Results
BU
Crescita Therapeutics Obtains TSX Approval for Normal Course Issuer Bid
MT
Crescita Therapeutics Brief: Announced Approval of Normal Course Issuer Bid
MT
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
BU
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.
CI
Crescita Therapeutics Inc. authorizes a Buyback Plan.
CI
- Crescita Therapeutics Brief: Q2 Revenue $5.162 Million; Ending cash was $10,226, down $49 for the quarter
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTX Stock
  4. News Crescita Therapeutics Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW